Product Description: SU6656 is a Src family kinases inhibitor with IC50s of 280, 20, 130, 170 nM for Src, Yes, Lyn, and Fyn, respectively. SU6656 inhibits FAK phosphorylation at Y576/577, Y925, Y861 sites. SU6656 also inhibits p-AKT.
Applications: Cancer-Kinase/protease
Formula: C19H21N3O3S
References: [1]Blake RA, et al. SU6656, a selective src family kinase inhibitor, used to probe growth factor signaling. Mol Cell Biol. 2000 Dec;20(23):9018-27./[2]Veracini L, et al. Elevated Src family kinase activity stabilizes E-cadherin-based junctions and collective movement of head and neck squamous cell carcinomas. Oncotarget. 2014 Dec 26./[3]Wu ML, et al. Divergent signaling pathways cooperatively regulate TGFβ induction of cysteine-rich protein 2 in vascular smooth muscle cells. Cell Commun Signal. 2014 Mar 28;12:22./[4]Ondrusová L, et al. Inhibition of mTORC1 by SU6656, the selective Src kinase inhibitor, is not accompanied by activation of Akt/PKB signalling in melanoma cells. Folia Biol (Praha). 2013;59(4):162-7./[5]Kumar A, et al. Pharmacological investigations on possible role of Src kinases in neuroprotective mechanism of ischemic postconditioning in mice. Int J Neurosci. 2014 Oct;124(10):777-86./[6]Liu XF, et al. Antitumor effects of immunotoxins are enhanced by lowering HCK or treatment with SRC kinase inhibitors. Mol Cancer Ther. 2014 Jan;13(1):82-9.
CAS Number: 330161-87-0
Molecular Weight: 371.45
Compound Purity: 98.05
Research Area: Cancer
Solubility: DMSO : 20 mg/mL (ultrasonic)
Target: Akt;FAK;Src
English
Deutsch
